Sabrina Clemens

Super interesting! We have observed changes in (hyper)vascularization many times during aging but never really followed it up. So cool to see these findings + amazing imaging: Reversible hypervascularization drives cognitive decline and blood-brain barrier damage during aging. Great work by @erturklab. Congrats! biorxiv.org/content/10.648…

@yaochen20 Well deserved!

Grateful to my lab members, colleagues, mentors, and collaborators for having such an impact on my research and teaching! This award is encouragement for me to keep making an impact with these wonderful people.

Big thanks to everyone involved on this project, especially @taylor_pedersen @BrianGordon81 @ErikMusiek

We do a deep dive into understanding wake-promoting neuromodulators norepinephrine, histamine, and orexin in Alzheimer's disease, interactions with sleep, and implications for brain fluid flow.

They say science is a team sport. I'm happy to share our collaborative, co-first, co-last author review is finally out in Alzheimer's & Dementia. alz-journals.onlinelibrary.wiley.com/doi/10.1002/al…

Blood test 'clocks' predict when Alzheimer’s symptoms will start source.washu.edu/2026/02/blood-…

Did they really need a citation for this?

Americans do not want to get drawn into another war in the Middle East. No war with Iran.

Midnight surgeries tonight 🕛 Big shout out to Anurag for his help! Truly a dedicated undergraduate researcher 💫

Your brain has a plot twist: WashU Medicine researchers have discovered that astrocytes — not neurons — may drive attention and alertness. This new science breakthrough could reshape how we treat ADHD, memory loss and more. medicine.washu.edu/news/overlooke…

Maybe there should be a different category: FDA-allowed, which then should go on to seek actual approval.

Bombshell report out about the US FDA. From 2013 to 2022, nearly three quarters of drugs approved had inadequate evidence of their efficacy. levernews.com/fda-approved-a…

They include a database where you can check on drugs approved during that time and how they rank based on whether drug trials were blinded, controlled, replicated, and clinically helpful. Lemborexant (Dayvigo) met all 4 criteria for insomnia. airtable.com/appo0jvZ8ONLJX…

@BrighamWomens @NPR Life's been good to him so far

79-year-old Joe Walsh is the first person living with Alzheimer's to get an experimental nasal spray treatment. Researchers at the Brigham are excited about the potential impact. Learn more in @NPR: npr.org/sections/shots…

🧠💤 Can better sleep protect the brain? New research from WashU shows that the sleep aid lemborexant improves rest and reduces harmful tau protein buildup—offering potential protection against Alzheimer’s disease. bit.ly/4jubE1Z

@asharma313 @_BrightFocus @ErikMusiek Congrats, Ashish!

I’m truly grateful to the @_BrightFocus Foundation for recognizing our research and supporting this journey. It’s an honor to be part of a community driving real progress together. Sincere thanks to @ErikMusiek for his invaluable guidance throughout.

Ashish Sharma, PhD, a BrightFocus Alzheimer's Disease Research grant recipient, is uncovering the connection between circadian rhythm disruptions and the accumulation of amyloid plaques and tau protein in the brain—two key Alzheimer's biomarkers. This research is deeply personal for Dr. Sharma, who watched a family member "slowly fade—first losing memories, then words, until even their ability to communicate was gone." 45% of Alzheimer's patients reporting sleep problems. Dr. Sharma's research could chart a path for earlier detection and new treatment approaches. Learn more: bit.ly/43Dz93P #Alzheimers #BrightFocusFoundation #CureInMind

George Carlin was right about golf.

🤠

This week I start the T32 training program with the @WashUMedADRC. I'm not sure who's more excited, me or my PI @ErikMusiek! Looking forward to uncovering more about Alzheimer's disease pathology @WashUdbbs